ClinicalTrials.Veeva

Menu

Maternal Serum Alpha-fetoprotein Level May Predict the Presence of Morbid Adherent Placenta

R

rasha medhat abdul-hady

Status

Unknown

Conditions

Placenta Accreta

Treatments

Diagnostic Test: Serum alpha-fetoproteine

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

The aim of the study is to compare between alpha-fetoproteine as a biological marker and between ultrasound and Doppler in prediction of morbid adherent placenta.

Full description

in pregnant women withe previous cesarean section, placenta previa and ultrasonographic finding of an abnormally adherent placenta dose maternal serum alpha-fetoprotein predict prenataly the presence of morbid adherent placenta accurately?

Enrollment

150 estimated patients

Sex

Female

Ages

20 to 39 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • pregnant women with history of scarred uterus

    • plcenta previa covering the scar of previous caesarean section as diagnosed by 2DU/S
    • Gestational age from 28wks to full term

Exclusion criteria

  • pregnant women with fetus with congenital anomalies

    • pregnant women with ovarian swelling
    • pregnant women with medical disease

Trial design

150 participants in 2 patient groups

Non_adherent plcenta
Description:
placenta separated within 15 minutes after delivery of fetus
Adherent placenta
Description:
placenta dosenot separated within 15 minutes after delivery of fetus
Treatment:
Diagnostic Test: Serum alpha-fetoproteine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems